Zacks Investment Research upgraded shares of Cutera (NASDAQ:CUTR) from a sell rating to a hold rating in a research note released on Tuesday, January 9th.
According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
Other research analysts also recently issued research reports about the stock. Maxim Group reiterated a hold rating on shares of Cutera in a research note on Wednesday, November 8th. Roth Capital lifted their price target on shares of Cutera from $41.00 to $47.00 and gave the stock a buy rating in a research note on Tuesday, September 12th. Finally, BidaskClub raised shares of Cutera from a hold rating to a buy rating in a report on Tuesday, December 12th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Cutera currently has an average rating of Buy and a consensus price target of $37.33.
Cutera (NASDAQ CUTR) opened at $49.90 on Tuesday. Cutera has a 12 month low of $18.50 and a 12 month high of $52.90. The stock has a market cap of $698.85, a P/E ratio of 66.53, a P/E/G ratio of 1.49 and a beta of 0.41.
Cutera (NASDAQ:CUTR) last issued its quarterly earnings results on Tuesday, November 7th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.34. Cutera had a net margin of 7.99% and a return on equity of 18.73%. The company had revenue of $38.17 million during the quarter, compared to the consensus estimate of $34.82 million. During the same quarter in the previous year, the firm earned $0.12 earnings per share. The firm’s quarterly revenue was up 26.1% on a year-over-year basis. analysts expect that Cutera will post 0.55 earnings per share for the current fiscal year.
In other news, insider James A. Reinstein sold 7,175 shares of Cutera stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $45.35, for a total value of $325,386.25. Following the transaction, the insider now directly owns 132,284 shares of the company’s stock, valued at approximately $5,999,079.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Miguel Pardos sold 10,000 shares of Cutera stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $46.70, for a total transaction of $467,000.00. Following the completion of the transaction, the executive vice president now directly owns 39,698 shares in the company, valued at $1,853,896.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,968 shares of company stock worth $1,274,346. 11.60% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Parallel Advisors LLC acquired a new position in shares of Cutera in the 3rd quarter valued at $117,000. State of Alaska Department of Revenue acquired a new position in shares of Cutera in the 4th quarter valued at $125,000. Legal & General Group Plc increased its holdings in shares of Cutera by 69.6% in the 3rd quarter. Legal & General Group Plc now owns 3,600 shares of the medical device company’s stock valued at $149,000 after acquiring an additional 1,477 shares during the period. Alambic Investment Management L.P. acquired a new position in shares of Cutera in the 4th quarter valued at $204,000. Finally, Greenwood Capital Associates LLC acquired a new position in shares of Cutera in the 3rd quarter valued at $210,000. 88.26% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/05/cutera-cutr-lifted-to-hold-at-zacks-investment-research.html.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Get a free copy of the Zacks research report on Cutera (CUTR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.